Tadalafil gehört zur Gruppe der PDE5-Hemmer und wirkt über eine hochselektive Blockade des Enzyms Phosphodiesterase Typ 5. Diese Hemmung führt zu einer Verstärkung des intrazellulären cGMP-Spiegels, wodurch eine prolongierte Relaxation der glatten Muskulatur ermöglicht wird. Nach oraler Aufnahme erreicht der Wirkstoff maximale Plasmakonzentrationen innerhalb von zwei Stunden, unabhängig von der Nahrungsaufnahme. Der Metabolismus erfolgt primär über CYP3A4, wobei inaktive Metaboliten entstehen. Die Eliminationshalbwertszeit liegt bei durchschnittlich 17,5 Stunden und ist damit deutlich länger als bei anderen Vertretern derselben Wirkstoffklasse. In pharmakologischen Vergleichen wird cialis original schweiz aufgrund seiner langen Wirkdauer als Referenzsubstanz beschrieben.

Mmc clinical trials_apr05

Memorial Medical Center1700 Coffee RoadModesto, CA 95355(209) 572-7237 Clinical Trials April 2005
BREAST:
IBCSG
A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for PremenopausalWomen with Endocrine Responsive Breast Cancer.
A Randomized Phase III Trial of Exemestane vs. Anastrozole With or Without Celecoxib in Postmenopausal Women with Receptor PositivePrimary Breast Cancer (** temporarily closed to accrual).
Quality of Life Companion Study for MA.27 (NEW)
A Clinical Trial Comparing Anastrozole with Tamoxifen in Postmenopausal Patients with Ductal Carcinoma In-Situ (DCIS)Undergoing Lumpectomy with Radiation Therapy.
A Phase III Adjuvant Trial Comparing Three Chemotherapy Regimens in Women with Node-Positive Breast Cancer: Docetaxel/Doxorubicin/Cyclophosphamide (TAC); Dose-Dense (DD) Doxorubicin/Cyclophospha-mide Followed by DD Paclitaxel (DD AC P); DD AC Followed byDD Paclitaxel Plus Gemcitabine (DD AC PG).
Phase III Trial of Observation +/- Tamoxifen vs. RT +/- Tamoxifen for Good Risk Duct Carcinoma In-Situ (DCIS) of the Female Breast.
Phase III Trial of Continuous Schedule AC + G vs. Every 2 WeekSchedule AC, Schedule AC, Followed by Paclitaxel Given Either Every 2Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy inNode-Positive or High-Risk Node Negative Breast Cancer.
Phase III Trial of Doxorubicin and Cyclophosphamide (AC) Followed byWeekly Paclitaxel With or Without Trastuzumab as Adjuvant Treatment forWomen with HER-2 Overexpressing or Amplified Node Positive or High-Risk Node Negative Breast Cancer.
GASTROINTESTINAL:
N0147
A Randomized Phase III Trial of Irinotecan (CPT-11) and/or
Oxaliplatin (OXAL)
Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) with or Without Cetuximab(C225) after Curative Resection for Patients with Stage III Colon Cancer.
Intergroup Randomized Phase III Study of Postoperative Irinotecan, 5-Fluorouracil and Leucovorin vs. Oxaliplatin, 5-Fluorouracil andLeucovorin vs. 5-Fluorouracil and Leucovorin for Patients with Stage IIor III Rectal Cancer Receiving Either Preoperative Radiation and5-Fluorouracil or Postoperative Radiation and 5-Fluorouracil(** temporarily closed to accrual).
A Randomized Phase III Study of Gemcitabine in Combination withRadiation Radiation Therapy versus Gemcitabine Alone in Patients withLocalized, Unresectable Pancreatic Cancer.
A Phase III Randomized Study of 5-Fluorouracil, Mitomycin-C, andRadiotherapy vs. 5-Fluorouracil, Cisplatin and Radiotherapy in Carcinomaof the Anal Canal.
CALGB Phase III Intergroup Trial of Adjuvant Chemoradiation After Resection of
80101
Gastric or Gastroesophageal Adenocarcinoma.
CALGB A Randomized Phase III Trial of Gemcitabine plus Bevacizumab vs.
80303
Gemcitabine plus Placebo in Patients with Advanced Pancreatic Cancer.
GENITOURINARY:
JPR.7
Phase III Randomized Trial Comparing Intermittent vs. ContinuousAndrogen Suppression for Patients with Prostate-Specific-AntigenProgression in the Clinical Absence of Distant Metastases FollowingRadiotherapy for Prostate Cancer.
LYMPHOMA:
E2496
A Randomized Phase III Trial of ABVD vs. Stanford V +/- Radiation Therapyin Locally Extensive and Advanced Stage Hodgkin’s Disease.
Randomized Phase III Trial Comparing Two Different Rituximab DosingRegimens for Patients with Low Tumor Burden Indolent non-Hodgkin’sLymphoma.
SKIN:
S0331
A Phase II Trial of STI-571/Imatinib (Gleevec) in NeuroendocrineCarcinoma of the Skin (Merkel Cell Carcinoma).
SYMPTOM MANAGEMENT:
E1Z01
Study of Epoetin Alpha vs. Epoetin Alpha with Dexamethasone inHormone Refractory Prostate Cancer Patients: Impact on Anemia,Fatigue, Functional Status and Quality of Life.
THORAX:
BR.19
A Phase III Prospective Randomized, Double-Blind, Placebo-ControlledTrial of the Epidermal Growth Factor Receptor Antagonist, ZD 1839(IRESSA) in Completely Resected Primary Stage IB, II, IIIA Non-SmallCell Lung Cancer.
A Phase III Trial of Carboplatin, Paclitaxel and Thoracic Radiotherapy,With or Without Thalidomide, in Patients with Stage III Non-Small CellLung Cancer.
Phase III Chemoprevention Trial of Selenium Supplementation in Personswith Resected Stage I Non-Small Cell Lung Cancer.
For any additional information regarding the above Clinical Trials, contact Denise Galbawy RN, Cancer Research Coordinator, at 572-7116.

Source: http://www.memorialmedicalcenter.org/images/MMC%20Clinical%20Trials_Apr05.pdf